Paolo Tralongo

ORCID: 0000-0003-0177-086X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Treatment and Pharmacology
  • Cancer survivorship and care
  • Palliative Care and End-of-Life Issues
  • Childhood Cancer Survivors' Quality of Life
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Prostate Cancer Treatment and Research
  • Breast Cancer Treatment Studies
  • Cancer Diagnosis and Treatment
  • Economic and Financial Impacts of Cancer
  • Cancer-related cognitive impairment studies
  • HER2/EGFR in Cancer Research
  • Genetic factors in colorectal cancer
  • Chemotherapy-related skin toxicity
  • Complementary and Alternative Medicine Studies
  • Gastric Cancer Management and Outcomes
  • BRCA gene mutations in cancer
  • Advanced Breast Cancer Therapies
  • Global Cancer Incidence and Screening
  • Advances in Oncology and Radiotherapy
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Estrogen and related hormone effects
  • Lung Cancer Research Studies
  • Radiopharmaceutical Chemistry and Applications
  • Herbal Medicine Research Studies

Ospedali Riuniti Umberto I
2015-2024

Università Cattolica del Sacro Cuore
2021

Associazione Italiana Di Oncologia Medica
2013-2019

Policlinico Umberto I
2016-2018

Medica (Italy)
2017

SIS Medical (Switzerland)
2006

Santa Maria Nuova Hospital
2003-2004

Villa Maria Hospital
2002-2004

University of South Florida
2002-2003

Moffitt Cancer Center
2002-2003

// Massimiliano Berretta 1 , Chiara Della Pepa 2 Paolo Tralongo 3 Alberto Fulvi 4 Ferdinando Martellotta Arben Lleshi Guglielmo Nasti 5 Rossella Fisichella 6 Carmela Romano De Divitiis Rosaria Taibi Francesco Fiorica 7 Raffaele Di Francia 8, 9 Anna Mari Lino Del Pup 10 Crispo 11 Paoli 12 Adriano Santorelli 13 Vincenzo Quagliariello Rosario Iaffaioli Umberto Tirelli Gaetano Facchini Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy Division Uro-Gynaecological...

10.18632/oncotarget.14224 article EN Oncotarget 2016-12-25

The number of people diagnosed with cancer who live longer than 5 years from diagnosis or end acute treatment, along the patients in a chronic state, is increasing industrialized countries. Consequently, survivorship care now an established branch oncology and growing health research priority. Yet, several gaps contemporary study were identifi ed through American Society ClinicalOncology(ASCO)electronicsurveyof679memberswho acted as principal coprincipal investigators survivorshiprelated...

10.1200/jco.2016.68.3870 article EN Journal of Clinical Oncology 2016-07-26

Purpose: Complementary and Alternative Medicine (CAM) interventions are widely used by patients with chronic disorders, including cancer, may interact cancer treatment. Physicians often unaware of this, probably due to poor patient-physician communication on CAM. The purpose this study was evaluate physicians' knowledge, attitudes practice patterns regarding CAM in a survey conducted Italy. Methods: A questionnaire administered 438 physicians (11 Italian hospitals) who predominantly treat...

10.3389/fonc.2020.00594 article EN cc-by Frontiers in Oncology 2020-04-28

This study was performed to determine the activity of adding continuous infusion (CI) 5-fluorouracil (5-FU) gemcitabine (GEM) vs GEM alone in advanced pancreatic cancer (APC). In all, 94 chemo-naïve patients with APC were randomised receive (arm A: 1000 mg m−2 per week for 7 weeks followed by a 2 rest period, then weekly 3 consecutive out every 4 weeks) or combination CI 5-FU B: 200 day−1 6 weeks). Overall response rate (RR) primary end point and criteria decision planned according Simon's...

10.1038/sj.bjc.6602640 article EN cc-by-nc-sa British Journal of Cancer 2005-06-28

Abstract: Patient-centered home care is a new model of assistance, which may be integrated with more traditional hospital-centered especially in selected groups informed and trained patients. based on patients' needs rather than prognosis, takes into account the emotional psychosocial aspects disease. This applied to elderly patients, who present comorbid diseases, but it also fits younger fit A specialized multidisciplinary team coordinated by experienced medical oncologists including...

10.2147/tcrm.s22119 article EN cc-by-nc Therapeutics and Clinical Risk Management 2011-09-01

A multidisciplinary panel of experts and cancer patients developed a position paper to highlight recent evidence on "cancer cure" (ie, the possibility achieving same life expectancy as general population) discuss consequences this concept follow-up rehabilitation strategies. The aim is inform clinicians, patients, health-care policy makers about strategies survivorship care for cured impacting patient lives, spurring public health authorities research organizations implement resources...

10.2147/cmar.s380390 article EN cc-by-nc Cancer Management and Research 2022-10-01

The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR). drug was delivered by Medtronic Synchromed implantable pump (Medtronic, Inc., Minneapolis, MN) in 14-day cycles alternating intervals heparinized physiologic saline infusion. the course 24 months 444 have been given for a total 12449 days function. observed at least 3 (range, to 23...

10.1002/1097-0142(19900715)66:2<237::aid-cncr2820660207>3.0.co;2-f article EN Cancer 1990-07-15

Long-term survival for adult patients with solid tumours continues to increase. For some cancers, the possibility of recurrence after a number years is extremely low, and risk death becomes similar that general population same sex age. During Fifth European Conference on Survivors Chronic Cancer Patients held in Siracusa, Italy, June 2014, oncologists, practitioners, epidemiologists, cancer survivors, patient advocates joined discuss possible use term “cured” reference tumours. The specific...

10.3747/co.22.2287 article EN cc-by Current Oncology 2015-02-01

Introduction: The advent of oral chemotherapy agents has had a strong impact on several aspects the management cancer patients, including survival rates, health-care expenditure, and health-related quality life. However, access to care adherence are central optimal outcomes. Patients methods: In this multicenter observational study, we assessed effect “Active Home Care” initiative – structured, active, home-based cancer-treatment program life, utilization, patient satisfaction using...

10.2147/ppa.s62666 article EN cc-by-nc Patient Preference and Adherence 2014-06-01

Abstract Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer ( mCRC ). Effective management of skin reactions from cetuximab quality life (QoL), and treatment compliance in clinical trials. No data are available real‐world settings. The ObservEr observational, multicenter, prospective study evaluated QoL, the incidence reactions, plus first‐line . primary endpoint was QoL measured with Dermatology Life Quality Index DLQI ) EORTC QLQ ‐C30. Secondary...

10.1002/cam4.888 article EN cc-by Cancer Medicine 2016-10-17

Background: Cancer incidence in the world is predicted to increase next decade. While progress has been diagnosis and treatment, much still remains be done improve cancer pain therapy, mainly underserved communities low-income countries. Objective: To determine knowledge, beliefs, barriers regarding management both high- countries (according WHO classification); learn about ways current state of affairs. Design: Descriptive survey. Setting/Subjects: Fifty-six worldwide; convenience sample...

10.1089/jpm.2021.0596 article EN Journal of Palliative Medicine 2022-04-20

&lt;i&gt;Background:&lt;/i&gt; To evaluate the effectiveness and tolerability of long-term treatment bone metastases with pamidronate in older patients. &lt;i&gt;Materials Methods:&lt;/i&gt; Twenty-two ambulatory patients aged 70 or were included study. The median age was 73 (range 70–77). Ten (46%) affected by breast carcinoma, 7 (32%) prostate carcinoma 5 (22%) multiple myeloma. Nine (40%) presented co-morbidity. All at least one metastatic lytic lesion measuring 1 cm more diameter; number...

10.1159/000080996 article EN Oncology 2004-01-01
Coming Soon ...